Leveraging Cutting‐Edge NULISA Technology for Proteomic Profiling and Biomarker Discovery in Autosomal Dominant Alzheimer's Disease
We have showed that NULISA platform produces reliable measurements, that are highly correlated to those obtained with established methods. Additionally, we demonstrated that utilizing this platform we replicated the known biomarkers, validating the use of NULISA assay in ADAD and DIAN. Additionally, we have identified new proteins associated with presence of AD-causal mutations or presence of AD symptoms. We are currently investigating trajectories of these proteins in the ADAD disease progression, as well as evaluating their potential as biomarkers.
Authors
- Celeste M M. Karch (ORCID: https://orcid.org/0000-0002-6854-5547)
- Bryce Baker
- Gina Jerome
- Matthew Minton
- Eric McDade (ORCID: https://orcid.org/0000-0002-6764-3866)
- Aleksandra Beric (ORCID: https://orcid.org/0000-0002-9351-585X)
- Jorge J. Llibre‐Guerra (ORCID: https://orcid.org/0000-0002-2137-7750)
- Sam Rose Preminger
- Wenjing Lin
- Jennifer Stauber
- Laura Ibanez
- Jason J. Hassenstab
- Carlos Cruchaga
- Chengjie Xiong
- Charlene Supnet‐Bell
- Randall J. Bateman
- Brian A. Gordon
Institutions
- Washington University in St. Louis (US)
- Hope Center for Neurological Disorders (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_099818
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00